DAVID E.I. PYOTT, M.D. (HON.) - Corporate Board Profile

BIOMARIN PHARMACEUTICAL INC

Filing Date	Source Excerpt
2017-04-25	David E.I. Pyott, M.D. (Hon.), 63, joined our Board in January 2016. Serves on Compensation Committee and Corporate Governance and Nominating Committee. 2016 Independent Director Compensation: $773,399.
2018-04-24	David E.I. Pyott, M.D. (Hon.), 64, January 2016, Lead Director, Avery Dennison Corporation; Director, Alynlam Pharmaceuticals, Inc.; Supervisory Board Member, Royal Philips
2019-04-23	David E.I. Pyott, M.D. (Hon.), 65, January 2016, Lead Director, Avery Dennison Corporation; Director, Alynlam Pharmaceuticals, Inc.; Supervisory Board Member, Royal Philips in the Netherlands
2020-04-14	David E.I. Pyott, M.D. (Hon.), joined our Board in January 2016. From 1998 to March 2015, Dr. Pyott served as Chief Executive Officer of Allergan, Inc., a global pharmaceutical company.
2021-04-13	David E.I. Pyott, M.D. (Hon.), joined our Board in January 2016. From 1998 to March 2015, Dr. Pyott served as Chief Executive Officer of Allergan, Inc., a global pharmaceutical company. The CGN Committee is currently composed of four directors, each of whom is “independent” under the listing standards of Nasdaq. The members of the CGN Committee are Dr. Heron (Chair), Ms. Anderson, Dr. Dere and Dr. Pyott. The Compensation Committee is currently composed of four directors: Mr. Grey (Chair), Ms. Anderson, Mr. Hombach and Dr. Pyott. 2020 INDEPENDENT DIRECTOR COMPENSATION: David E.I. Pyott, M.D. (Hon.) Fees Earned ($) 83,750 Stock Awards ($) 458,810 Total ($) 542,560.
2022-04-12	David E.I. Pyott, M.D. (Hon.), 68, Director Since January 2016, Director, Alynlam Pharmaceuticals, Inc.; Director, Pliant Therapeutics, Inc.; Supervisory Board Member, Royal Philips in the Netherlands. Compensation Committee Member. CGN Committee Member. 2021 INDEPENDENT DIRECTOR COMPENSATION: Fees Earned or Paid in Cash $83,750, Stock Awards $397,312, Total $481,062.
2023-04-11	David E.I. Pyott, M.D. (Hon.) joined our Board in January 2016. Dr. Pyott served as CEO of Allergan, Inc., a global pharmaceutical company, from 1998 to March 2015. Prior to Allergan, Dr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of Switzerland-based Novartis AG. Dr. Pyott serves on the boards of Alnylam Pharmaceuticals, Inc., a public biotechnology company and Pliant Therapeutics, Inc., a public biopharmaceutical company, and is a member of the Supervisory Board of Royal Philips in the Netherlands, a public diversified health and technology company. Dr. Pyott is Deputy Chairman of the Governing Board of the London Business School, serves on the board of the Pan American Ophthalmological Foundation, is a member of the Board of Trustees of the California Institute of Technology, President of the advisory board of the Foundation of American Academy of Ophthalmology and President of the Ophthalmology Foundation. Dr. Pyott formerly served on the board of Avery Dennison Corporation, a public global labeling and packaging materials company, from 1999 through April 2020. Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School.
2024-04-09	David E.I. Pyott, M.D. (Hon.), joined our Board in January 2016. ... 2023 Independent Director Compensation ... David E.I. Pyott, M.D. (Hon.) 85,000 Fees Earned or Paid in Cash, 385,438 Stock Awards, 470,438 Total.